Selpercatinib

Selpercatinib, sold under the brand name Retevmo among others, is a medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET which is short for "rearranged during transfection").[3][4][5] It is taken by mouth.[3]

Selpercatinib
Clinical data
Trade namesRetevmo, Retsevmo
Other namesLOXO-292
AHFS/Drugs.comMonograph
MedlinePlusa620036
License data
Pregnancy
category
  • Use should be avoided
Routes of
administration		By mouth
Drug classTyrosine kinase inhibitor
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • 6-(2-hydroxy-2-methylpropoxy)-4- (6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3- yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H31N7O3
Molar mass525.613 g·mol−1
3D model (JSmol)
SMILES
  • COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
InChI
  • InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3
  • Key:XIIOFHFUYBLOLW-UHFFFAOYSA-N

The most common side effects include changes in laboratory tests (including increased liver enzymes, increased blood sugar, decreased white cell and platelet counts, decreased protein level, decreased calcium, increased total cholesterol, increased creatinine, and decreased sodium) dry mouth, diarrhea, high blood pressure, fatigue, edema, rash, and constipation.[3][5][6]

Selpercatinib is a kinase inhibitor, meaning it blocks a type of enzyme (kinase) and helps prevent the cancer cells from growing.[3][5] Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing.[3][5]

Selpercatinib is the first therapy approved specifically for people with cancer and the RET gene alterations.[5]

Medical uses

In the United States, selpercatinib is indicated for the treatment of:[3]

  • adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.[3][5][6][7]
  • people aged twelve years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.[3][5][6]
  • people aged twelve years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).[3][5][6]
  • adults with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.[3][8]

In the European Union, selpercatinib, as monotherapy, is indicated for the treatment of adults with:[4]

  • advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy[4]
  • advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib[4]

and for the treatment of people aged twelve years of age and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.[4]

Adverse effects

Selpercatinib can cause serious side effects including liver toxicity, high blood pressure, heart rhythm changes due to prolongation of heart electrical activity (QT prolongation), bleeding, allergic reactions, impaired wound healing and harm to an unborn baby.[3][5][6]

Selpercatinib may cause harm to a developing fetus or a newborn baby.[3][5]

History

Selpercatinib was approved for medical use in the United States in May 2020.[5][9][10][6]

Selpercatinib was approved based on the results of the LIBRETTO-001 clinical trial (NCT03157128) involving 702 participants aged 15–92 years with each of the three types of tumors.[5][10][6] During the clinical trial, participants received 160 mg selpercatinib orally twice daily until disease progression or unacceptable toxicity.[5] The major efficacy outcome measures were overall response rate (ORR), which reflects the percentage of participants that had a certain amount of tumor shrinkage, and duration of response (DOR).[5] The trial was conducted at 84 sites in the United States, Canada, Australia, Hong Kong, Japan, South Korea, Singapore, Taiwan, Switzerland, Germany, Denmark, Spain, France, the United Kingdom, Italy and Israel.[6] The conversion to regular approval for non-small cell lung cancer (NSCLC) was based on data from an additional 172 participants and 18 months of additional follow-up to assess durability of response.[7]

Efficacy for non-small cell lung cancer (NSCLC) was evaluated in 105 adult participants with rearranged during transfection (RET) fusion-positive NSCLC who were previously treated with platinum chemotherapy.[5] Sixty-four percent of the 105 participants with previously treated NSCLC, experienced complete or partial shrinkage of their tumors which lasted more than six months for 81% of them.[6] Out of 39 participants who had never undergone treatment, 84% experienced complete or partial shrinkage of their tumors which lasted more than six months for 58% of them.[6]

Efficacy for medullary thyroid cancer (MTC) was evaluated in participants 12 years of age and older with RET-mutant MTC .[5] The study enrolled 143 participants with advanced or metastatic RET-mutant MTC who had been previously treated with cabozantinib, vandetanib or both (types of chemotherapy), and participants with advanced or metastatic RET-mutant MTC who had not received prior treatment with cabozantinib or vandetanib.[5] Sixty-nine percent of the 55 previously treated participants for MTC experienced complete or partial shrinkage of their tumors which lasted more than 6 months for 76% of them.[6] Out of 88 participants who had never undergone treatment with an approved drug, 73% experienced complete or partial shrinkage of their tumors which lasted more than six months for 61% of them.[6]

Efficacy for rearranged during transfection (RET) fusion-positive thyroid cancer was evaluated in participants 12 years of age and older.[5] The study enrolled 19 participants with RET fusion-positive thyroid cancer who were radioactive iodine-refractory (RAI, if an appropriate treatment option) and had received another prior systemic treatment, and eight participants with RET fusion-positive thyroid cancer who were RAI-refractory and had not received any additional therapy.[5] Seventy-nine percent of the 19 previously treated participants with thyroid cancer experienced complete or partial shrinkage of their tumors which lasted more than six months for 87% of them.[6] All eight participants who had not received therapy other than radioactive iodine therapy experienced complete or partial shrinkage of their tumors which lasted more than six months for 75% of them.[6]

Efficacy for locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options was demonstrated in LIBRETTO-001 (NCT03157128), a multicenter, open-label, multi-cohort trial that evaluated 41 participants with RET fusion-positive tumors (other than non-small cell lung cancer and thyroid cancer) with disease progression on or following prior systemic treatment or who had no satisfactory alternative treatment options.[8] The efficacy evaluation was supported by data in 343 participants with RET fusion-positive NSCLC and thyroid cancer enrolled in the same trial already described in product labeling.[8] Participants received selpercatinib until disease progression or unacceptable toxicity.[8]

The US Food and Drug Administration (FDA) granted the application for selpercatinib priority review, orphan drug, and breakthrough therapy designations;[5][11] and granted approval of Retevmo to Loxo Oncology, Inc., a subsidiary of Eli Lilly and Company.[5]

On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Retsevmo, intended for the treatment of cancers that display rearranged during transfection (RET) gene alterations: RET-fusion positive non-small cell lung cancer (NSCLC), RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer (MTC).[12] The applicant for this medicinal product is Eli Lilly Nederland B.V. Selpercatinib was approved for medical use in the European Union in February 2021.[4]

References
  1. "Summary Basis of Decision (SBD) for Retevmo". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  2. "Retsevmo 40 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 27 June 2022. Archived from the original on 25 February 2022. Retrieved 22 September 2022.
  3. "Retevmo- selpercatinib capsule". DailyMed. Archived from the original on 4 March 2021. Retrieved 31 March 2021.
  4. "Retsevmo EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 23 April 2021. Retrieved 23 April 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. "FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion" (Press release). U.S. Food and Drug Administration (FDA). 8 May 2020. Archived from the original on 9 May 2020. Retrieved 8 May 2020. This article incorporates text from this source, which is in the public domain.
  6. "Drug Trials Snapshots: Retevmo". U.S. Food and Drug Administration (FDA). 8 May 2020. Archived from the original on 20 October 2020. Retrieved 1 June 2020. This article incorporates text from this source, which is in the public domain.
  7. "FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer" (Press release). U.S. Food and Drug Administration (FDA). 21 September 2022. Archived from the original on 22 September 2022. Retrieved 22 September 2022. This article incorporates text from this source, which is in the public domain.
  8. "FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors" (Press release). U.S. Food and Drug Administration (FDA). 21 September 2022. Archived from the original on 22 September 2022. Retrieved 22 September 2022. This article incorporates text from this source, which is in the public domain.
  9. "Drug Approval Package: Retevmo". U.S. Food and Drug Administration (FDA). 7 August 2020. Archived from the original on 18 January 2022. Retrieved 22 September 2022.
  10. "Lilly Receives U.S. FDA Approval for Retevmo (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers" (Press release). Eli Lilly and Company. 8 May 2020. Archived from the original on 9 May 2020. Retrieved 8 May 2020 – via PR Newswire.
  11. "FDA approves selpercatinib for lung and thyroid cancers with RET gene". U.S. Food and Drug Administration (FDA). 8 May 2020. Archived from the original on 12 May 2020. Retrieved 11 May 2020. This article incorporates text from this source, which is in the public domain.
  12. "Retsevmo: Pending EC decision". European Medicines Agency (EMA). 11 December 2020. Archived from the original on 11 December 2020. Retrieved 11 December 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.